Abstract:Increasing evidence suggests a role of intestinal dysbiosis in obesity and non-alcoholic fatty liver disease (NAFLD). But it remains unknown in nonobese NAFLD. This prospective, cross-sectional study sought to characterize differences in fecal microbiota between nonobese adult individuals with and without NAFLD and their potential association with metabolic markers of disease progression. A total of 126 nonobese subjects were enrolled: 43 NAFLD and 83 healthy controls (HC). The microbial community was profiled… Show more
“…However, studies have demonstrated contradictory findings in the relative abundance of Ruminococcus , Prevotella , and Bifidobacterium . Only one study has evaluated the gut microbiota in non-obese adults and found a decrease in Lactobacillus 15 , contrary to findings in obese NAFL.…”
Section: Human Gut Microbiome Profiles In Clinical Phenotypes Of Naflmentioning
confidence: 77%
“…In NAFL, comparison groups included healthy controls 9,8,10,11,15,16,18,23 and obese controls 21 . In NASH, comparison groups included healthy controls 9,10,12,13,18,19 , obese controls 7 , and NAFL 24,16 .…”
Section: Figurementioning
confidence: 99%
“…In NAFLD-associated advanced fibrosis, comparison groups included healthy controls 20 and NAFLD without advanced fibrosis (stage<2) 17,24,22,16 . In NAFLD-related HCC, the comparison group included NAFLD-related cirrhosis without HCC 20 .
+
The fecal and serum metabolites listed are postulated to be derived from the gut microbiome.
±
Two studies enrolled only non-obese subjects, in order to examine compositional changes in non-obese (“lean”) NAFL 15 and NASH 19 .
Abbreviations : nonalcoholic fatty liver disease (NAFLD), nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC).
…”
The gut microbiome, a diverse microbial community in the gastrointestinal tract, plays a pivotal role in the maintenance of health. The gut microbiome metabolizes dietary and host-derived molecules to produce bioactive metabolites, which have a wide array of effects on host metabolism and immunity. 'Dysbiosis' of the gut microbiome, commonly considered as perturbation of microbiome diversity and composition, has been associated with intestinal and extra-intestinal diseases, including nonalcoholic fatty liver disease (NAFLD). A number of endogenous and exogenous factors, such as nutritional intake and xenobiotic exposure, can alter the gut microbiome. We will review the evolving methods for studying the gut microbiome and how these profiling techniques have been utilized to further our understanding of the gut microbial community composition and functional potential in the clinical spectrum of NAFLD. We will highlight microbiome-host interactions that may contribute to the pathogenesis of NAFLD, with a primary focus on mechanisms related to the metabolic output of the gut microbiome. Finally, we will discuss potential therapeutic implications of the gut microbiome in NAFLD.
“…However, studies have demonstrated contradictory findings in the relative abundance of Ruminococcus , Prevotella , and Bifidobacterium . Only one study has evaluated the gut microbiota in non-obese adults and found a decrease in Lactobacillus 15 , contrary to findings in obese NAFL.…”
Section: Human Gut Microbiome Profiles In Clinical Phenotypes Of Naflmentioning
confidence: 77%
“…In NAFL, comparison groups included healthy controls 9,8,10,11,15,16,18,23 and obese controls 21 . In NASH, comparison groups included healthy controls 9,10,12,13,18,19 , obese controls 7 , and NAFL 24,16 .…”
Section: Figurementioning
confidence: 99%
“…In NAFLD-associated advanced fibrosis, comparison groups included healthy controls 20 and NAFLD without advanced fibrosis (stage<2) 17,24,22,16 . In NAFLD-related HCC, the comparison group included NAFLD-related cirrhosis without HCC 20 .
+
The fecal and serum metabolites listed are postulated to be derived from the gut microbiome.
±
Two studies enrolled only non-obese subjects, in order to examine compositional changes in non-obese (“lean”) NAFL 15 and NASH 19 .
Abbreviations : nonalcoholic fatty liver disease (NAFLD), nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC).
…”
The gut microbiome, a diverse microbial community in the gastrointestinal tract, plays a pivotal role in the maintenance of health. The gut microbiome metabolizes dietary and host-derived molecules to produce bioactive metabolites, which have a wide array of effects on host metabolism and immunity. 'Dysbiosis' of the gut microbiome, commonly considered as perturbation of microbiome diversity and composition, has been associated with intestinal and extra-intestinal diseases, including nonalcoholic fatty liver disease (NAFLD). A number of endogenous and exogenous factors, such as nutritional intake and xenobiotic exposure, can alter the gut microbiome. We will review the evolving methods for studying the gut microbiome and how these profiling techniques have been utilized to further our understanding of the gut microbial community composition and functional potential in the clinical spectrum of NAFLD. We will highlight microbiome-host interactions that may contribute to the pathogenesis of NAFLD, with a primary focus on mechanisms related to the metabolic output of the gut microbiome. Finally, we will discuss potential therapeutic implications of the gut microbiome in NAFLD.
“…It has been reported that fecal samples from colon cancer patients had less bacterial diversity compared with samples from healthy individuals and a lower amount of bacterial diversity in the gut may indicate a lack of balance in the complex bacterial population30. Findings also showed that the non-obese patients with nonalcoholic fatty liver disease were characterized by a decrease in gut microbial diversity31. As shown in our data, a significant decrease in the Simpson index (alpha diversity) was only observed in STZ-HFD male mice relative to controls (Supplementary Table S1), which may be a reason why the male mice had a higher risk of developing HCC relative to females.…”
Emerging evidence points to a strong association between sex and gut microbiota, bile acids (BAs), and gastrointestinal cancers. Here, we investigated the mechanistic link between microbiota and hepatocellular carcinogenesis using a streptozotocin-high fat diet (STZ-HFD) induced nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC) murine model and compared results for both sexes. STZ-HFD feeding induced a much higher incidence of HCC in male mice with substantially increased intrahepatic retention of hydrophobic BAs and decreased hepatic expression of tumor-suppressive microRNAs. Metagenomic analysis showed differences in gut microbiota involved in BA metabolism between normal male and female mice, and such differences were amplified when mice of both sexes were exposed to STZ-HFD. Treating STZ-HFD male mice with 2% cholestyramine led to significant improvement of hepatic BA retention, tumor-suppressive microRNA expressions, microbial gut communities, and prevention of HCC. Additionally the sex-dependent differences in BA profiles in the murine model can be correlated to the differential BA profiles between men and women during the development of HCC. These results uncover distinct male and female profiles for gut microbiota, BAs, and microRNAs that may contribute to sex-based disparity in liver carcinogenesis, and suggest new possibilities for preventing and controlling human obesity-related gastrointestinal cancers that often exhibit sex differences.
“…Adipose tissue releases cytokines to increase inflammation and fibrosis. Gut microbiota is also believed to play a role in the development of NASH via alterations in the BA pool level and composition (Jiang et al, 2015; Liu et al, 2016b; Mei et al, 2015; Wang et al, 2016). Recently, vitamin D deficiency has been proposed as another possible factor as mice fed a high fat diet (HFD) exhibited increased steatosis and hepatic ballooning when coupled with a vitamin D deficiency (Kong et al, 2014).…”
Nonalcoholic fatty liver disease is growing in prevalence worldwide. It is started by the presence of macrosteatosis on liver histology but is often clinically asymptomatic. However, it can progress into nonalcoholic steatohepatitis which is a more severe form of liver disease characterized by inflammation and fibrosis. Further progression leads to cirrhosis, which predisposes patients to hepatocellular carcinoma or liver failure. The mechanism by which simple steatosis progresses to steatohepatitis is not entirely clear. However, multiple pathways have been proposed. A common link amongst many of these pathways is disruption of the homeostasis of bile acids. Other than aiding in the absorption of lipids and lipid-soluble vitamins, bile acids act as ligands. For example, they bind to farnesoid X receptor, which is critically involved in many of the pathways responsible for maintaining bile acid, glucose, and lipid homeostasis. Alterations to these pathways can lead to deregulation in energy balance and increased inflammation and fibrosis. Repeated insults over time may be the key to development of steatohepatitis. For this reason, current drugs target aspects of these pathways to try to reduce and halt inflammation and fibrosis. This review will focus on the role of bile acids in these various pathways and how changes in these pathways may result in steatohepatitis. While there is no approved pharmaceutical treatment for either hepatic steatosis or steatohepatitis, this review will also touch upon the multitude of potential therapies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.